Citigroup Maintains Microchip Technology Incorporated

Citigroup maintained a Buy rating on Microchip Technology Incorporated - Preferred Stock (MCHPP) on November 7, 2025, with an average one-year price target of $72.00/share, suggesting a 35.51% upside from its latest closing price of $53.13. Institutional sentiment is largely positive, with the number of funds holding MCHPP increasing by 12.20% and total institutional shares rising by 7.70% to 53,445K in the last quarter.

Analysis

Citigroup has reiterated a "Buy" recommendation for Microchip Technology Incorporated - Preferred Stock (MCHPP) as of November 7, 2025, signaling continued confidence in the security. The average one-year price target stands at $72.00/share, implying a substantial 35.51% upside from its recent closing price of $53.13/share. This target range, from $56.00 to $87.33, suggests a broad consensus for appreciation.

Investor sentiment for MCHPP appears robust, evidenced by significant institutional accumulation. The number of funds holding positions increased by 12.20% (15 new owners) in the last quarter, bringing the total to 138 institutions. Concurrently, total institutional shares rose by 7.70% to 53,445K, and the average portfolio weight dedicated to MCHPP increased by 38.92% to 0.37%.

While overall institutional interest is positive, individual fund actions show some divergence; for instance, Capital International Investors increased its allocation by 17.03%, whereas Voya Investment Management decreased its allocation by 58.06%. The projected annual non-GAAP EPS of $1.27 provides a fundamental basis for valuation, supporting the analyst's positive outlook and the general bullish sentiment among institutions.

Key Decisions for Investors

• Consider MCHPP for potential capital appreciation given the maintained "Buy" rating and significant average price target upside of 35.51%.
• Monitor institutional flow and individual fund conviction, noting the overall increase in ownership alongside specific divergent actions like Voya's reduced allocation.
• Evaluate MCHPP's fundamentals, particularly the projected non-GAAP EPS of $1.27, against industry peers to validate the analyst's valuation and long-term outlook.